Your Health, We Care
Release date: 2024-12-05 16:12:01 Recommended: 89
Advances in the field of cancer treatment are changing the way cancer is treated.
One example of a major advance is Asciminib (Scemblix, Asciminib), an innovative targeted therapy that offers hope to individuals with chronic myeloid leukemia (CML).
Chronic myeloid leukemia is a type of cancer that affects blood cells, particularly the bone marrow and peripheral blood. It is characterized by the uncontrolled growth of myeloid cells, mainly granulocytes.
The Philadelphia chromosome is a genetic abnormality caused by a translocation event between chromosomes 9 and 22, which is responsible for triggering the condition.
Translocation leads to the production of the BCR-ABL1 fusion gene. This genetically encoded tyrosine kinase is always active and plays a key role in the development of CML.
for the treatment of chronic myeloid leukemia), tyrosine kinase inhibitors (TKIs) have been the standard approach. These drugs target aberrant BCR-ABL1 kinase activity.
The utilization of TKIs has led to a significant shift in the treatment of CML, providing benefits of prolonged disease control and enhanced survival. However, the presence of resistance and intolerance to these drugs still poses a significant barrier.
Asimini marks a fundamental change in CML treatment.
Asciminib exerts its inhibitory effect by allosteric binding and does not compete with the ATP-binding site of the BCR-ABL1 kinase domain as typical TKIs do.
The unique approach employed by Asiminib allows it to selectively target BCR-ABL1, even in its active conformation, thus circumventing the mechanisms of resistance typically observed with ATP-competitive inhibitors.
Preclinical studies have provided evidence of strong and specific inhibition of BCR-ABL1 by asciminib, even in the presence of mutant variants that have shown resistance to standard tyrosine kinase inhibitors (TKIs).
In addition, asciminib exhibits favorable pharmacokinetic properties that contribute to its use as an oral treatment option with a simple dosing regimen.
The clinical effectiveness of assiminib in chronic myeloid leukemia was evaluated by clinical trials that included patients who had previously developed resistance or intolerance to tyrosine kinase inhibitor (TKI) therapy.
The ASCHEMB study has shown remarkable results, with many patients achieving a profound and long-lasting response when taking asiminib as the sole treatment.
The use of asimminib in the ASCEMBL study resulted in significant rates of major molecular response (MMR) and complete cytogenetic response (CCyR), which are important indicators for the management of chronic myeloid leukemia disease.
In addition, it is important to note that the safety profile of asciminib is predominantly positive, as the majority of patients experience manageable adverse effects.
